Ribosomal Protein rpL40 Modulation for Skin Elasticity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments lack the ability to effectively increase production of elastin and elastic fibers in skin cells, leading to issues with skin elasticity, texture, and wound-healing capabilities, particularly in aging and damaged skin.

Innovation Solution

A method is developed to identify and utilize compounds that modulate the rpL40-dependent translation of tropoelastin mRNA in mammalian cells, using a screening system to find cosmetically and pharmaceutically active compounds that bind to ribosomal protein rpL40, thereby enhancing tropoelastin production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If current treatments are used, then skin structure is maintained, but elastin production cannot be effectively increased

Engineering Contradiction:
Improveelastin productionVSAvoidtreatment effectiveness
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent changes the molecular parameter of ribosomal protein rpL40 interaction to selectively modulate tropoelastin translation. By identifying compounds that specifically bind to rpL40 and enhance its interaction with tropoelastin mRNA, the treatment achieves increased elastin production through a novel molecular mechanism not accessible by conventional therapies.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces small molecule compounds as intermediaries that mediate between the ribosomal protein rpL40 and tropoelastin mRNA. These compounds act as molecular bridges that enhance the specificity and efficiency of translation, enabling targeted increase of elastin production without affecting other proteins.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If conventional cosmetic treatments are applied, then skin appearance is maintained, but wound-healing capabilities deteriorate with aging

Engineering Contradiction:
Improvewound-healing capabilityVSAvoidskin elasticity duration
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by enhancing tropoelastin production before wound healing is needed. By continuously increasing elastin synthesis through rpL40 modulation, the skin maintains better structural integrity and elasticity over time, creating a reservoir of elastic fibers that support future wound healing and prevent age-related deterioration.

Inventive Principle:
Principle #10Preliminary action

3Strength

If elastin production is increased, then skin elasticity improves, but treatment complexity increases

Engineering Contradiction:
Improveskin elasticityVSAvoidtreatment mechanism complexity
Core Design Contradiction:
StrengthVSDevice complexity

Solution Approach 1:

The patent extracts the specific function of rpL40 in tropoelastin translation from the complex ribosomal system. By identifying and targeting this single ribosomal protein with specific small molecule compounds, the treatment isolates the critical control point for elastin production, simplifying the therapeutic approach while achieving selective enhancement of skin elasticity.

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively increases tropoelastin production, improving skin elasticity, texture, and wound-healing capabilities, addressing the deficiencies in existing treatments by targeting the ribosomal protein rpL40 to customize protein expression.

Implementation Method 1

modulates the rpL40-dependent translation of at least one mRNA encoding for tropoelastin in a mammalian cell

Methodology Applied
Scientific EffectTranslation:

Implementation Method 2

compounds that bind to ribosomal protein rpL40

Methodology Applied
Scientific EffectBinding: Absorption (physical)

Data Source

PatentEP4368729A1Molecules targeting ribosomal protein RPL40 for use in cosmetics and the treatment of diseases of the skin
Publication Date: 2024.05.15 SUSONITY COMMERCIAL GMBH
  • EP4368729A1 patent drawingFigure 1
  • EP4368729A1 patent drawingFigure 2
  • EP4368729A1 patent drawingFigure 3

AI summary

The present invention relates to a method for identifying a pharmaceutically or cosmetically active compound that modulates the rpL40-dependent translation of at least one mRNA encoding for tropoelastin in a mammalian cell. Furthermore, a respective screening system, methods of treating or preventing a disease or condition, and compounds as identified that modulate the rpL40-dependent translation as well synergistic combinations thereof are provided. In a preferred aspect, the cosmetically active compound is used in anti-aging products and strategies.